Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Capitalize on Breakthrough Therapy Designation Shifts: Benchmark Pfizer, Roche, Novartis, Merck and AstraZeneca to Accelerate Approvals, Defend Pipeline ROI and Capture Revenue

globenewswire.com
PFE Mentioned as a company that can capitalize on Breakthrough Therapy Designation shifts, suggesting potential for accelerated approvals and pipeline defense. MRK Mentioned as a company that can leverage Breakthrough Therapy Designation shifts for accelerated drug approvals and enhanced pipeline ROI. AZN Highlighted as a company that can capitalize on Breakthrough Therapy Designation shifts, indicating potential for faster approvals and pipeline defense.

Capitalize on Breakthrough Therapy Designation Shifts: Benchmark Pfizer, Roche, Novartis, Merck and AstraZeneca to Accelerate Approvals, Defend Pipeline ROI and Capture Revenue Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Breakthrough Therapy (BT) Designation - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.

The global market for Breakthrough Therapy (BT) Designation was estimated at US$79.7 Billion in 2025 and is projected to reach US$212.5 Billion by 2032, growing at a CAGR of 15.0% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

The Breakthrough Therapy (BT) designation is transforming the drug development landscape by providing a fast-track approval process for therapies that show significant potential in treating serious or life-threatening conditions. Introduced by the U.S. Food and Drug Administration (FDA) in 2012, the BT designation is designed to expedite the development and review of new drugs that demonstrate substantial improvement over existing therapies in early clinical trials. This designation provides sponsors with more frequent FDA communication, priority review, and access to senior FDA officials, all aimed at accelerating the drug approval process and bringing innovative treatments to patients more quickly.

BT designation is particularly beneficial for therapies targeting unmet medical needs, such as rare diseases, cancers, and chronic conditions that currently lack effective treatment options. For example, several immunotherapies and targeted therapies for cancer have received BT designation due to their ability to achieve higher response rates and improve patient outcomes compared to standard treatments. By shortening the time between clinical development and market approval, BT designation allows patients with serious conditions to access life-saving or life-altering therapies sooner, while also encouraging pharmaceutical companies to invest in groundbreaking research.

Report Scope

The report analyzes the Breakthrough Therapy (BT) Designation market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:

Key Insights:

Why You Should Buy This Report:

Key Questions Answered:

Report Features:

Some of the companies featured in this Breakthrough Therapy (BT) Designation market report include:

Domain Expert Insights

This market report incorporates insights from domain experts across enterprise, industry, academia, and government sectors. These insights are consolidated from multilingual multimedia sources, including text, voice, and image-based content, to provide comprehensive market intelligence and strategic perspectives. As part of this research study, the publisher tracks and analyzes insights from 18,810 domain experts. Clients may request access to the network of experts monitored for this report, along with the online expert insights tracker.

For more information about this report visit https://www.researchandmarkets.com/r/feqvjj

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.